Backed by a biotech legend, two young entrepreneurs tackle one of the Holy Grails of R&D
It’s not often that two recent college grads can come up with enough cash and connections to run a Phase II study of a new combination drug for a tough and deadly disease like ALS. But with some backing by biotech legend Henri Termeer and $8 million in venture cash and grant money, Justin Klee and Josh Cohen say they’re ready to turn what started out as an undergraduate science project at Brown into a clinical reality in a matter of months at a startup dubbed Amylyx.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
